XELTIS BV news

Xeltis announced today that is planning to accelerate its clinical trial program for three restorative devices in parallel. CEO Eliane Schutte provided a sneak preview on Xeltis’ plans to an audience of investors and medtech companies at the Medtech and Diagnostics Forum organised by the investment bank Canaccord Genuity Capital Markets.

Xeltis currently has three restorative devices in clinical trial phase, including aXess – a restorative access graft for dialysis; XABG &

Vascular surgeon and professor of vascular surgery at Università dell’Insubria in Italy, and Frans L. Moll, MD, PhD, professor emeritus of vascular surgery at the University Medical Center Utrecht in The Netherlands, provided insights on the progress of the aXess trial in an interview with Healio Nephrology.

For more on Xeltis’ aXess, the first restorative synthetic hemodialysis access graft, on the unmet research needs that the aXess trial is ai

Xeltis will receive €15 million in funding from the European Innovation Council Accelerator (EIC) set up by the European Commission. The EIC funding comprises €2.5 millions in grants and up to €12.5 millions in equity and will support Xeltis’ clinical trial program for its XABG device, the first-ever restorative Coronary Artery Bypass Graft (CABG).

XABG is a restorative, synthetic blood vessel device that turns into a living blood vessel when colonised by patient&

Xeltis has initiated the clinical trial for aXess, the first-ever restorative synthetic haemodialysis access graft. Several patients with kidney failure or advanced kidney disease requiring dialysis have already been successfully implanted as part of a European first-in-human trial to date.

The aXess grafts enable early puncturing, or initiation of the dialysis, shortly after implanting. Overtime, they turn into living blood vessels, as their porous micro-structure get colonized by th

To learn how Xeltis’ restorative hemodialysis access graft, aXess, may be opening new horizons for patients with kidney failure, tune in the Visionary Endovascular and Vascular Education (VERVE) Symposium in Sidney, up to 4 December.

In his talk on Saturday 4 December (10am AET), Professor Frans L. Moll, University Medical Center, Utrecht (NL) will explain how the Xeltis synthetic device may potentially enable an immediate start of hemodialysis upon diagnosis and avoid infection